The Fund aims to achieve capital growth over the long term by investing in a concentrated range of companies within the FTSE All Share Index. The Fund has a flexible asset allocation policy, meaning that it will not be constrained by the benchmark index.
Name | % Net Assets |
---|---|
GlaxoSmithKline | 6.2% |
BP | 5.0% |
Royal Dutch Shell | 4.6% |
UBM | 4.2% |
Tyman plc | 4.1% |
Henry Boot | 3.9% |
Goals | 3.7% |
Balfour Beatty | 3.1% |
Reed Elsevier | 3.0% |
Hays | 3.0% |
Key | % Net Assets |
---|---|
GlaxoSmithKline | 6.2% |
BP | 5.0% |
Royal Dutch Shell | 4.6% |
UBM | 4.2% |
Other | 80% |
Date | 13-Apr-2017 |
---|---|
NAV | 252.15p |
Currency | GBP |
Change | 0.000p |
% | n/a |
YTD change | 252.15p |
YTD % | n/a |
Fund Inception | 14/05/2004 |
---|---|
Fund Manager | Matthew Tillet |
TER | 1.99 (31-Aug-2013) |
Minimum Investment | |
---|---|
Initial | £500 |
Additional | £500 |
Savings | £50 |
Charges | |
---|---|
Initial | 4.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.04 |
You are here: research